Search the Newsreel

Aquestive Therapeutics (NASDAQ:AQST) Lowered to "Sell" Rating by Wall Street Zen

Aquestive Therapeutics (NASDAQ:AQST) has been downgraded from a "hold" to a "sell" rating by Wall Street Zen analysts. The company reported a Q2 earnings per share miss of ($0.18) against an estimated ($0.10), although revenue of $13.82 million exceeded the $11.42 million consensus. Despite …

Quest Resource’s Q2 Earnings Call: Our Top 5 Analyst Questions

Quest Resource (QRHC) reported notable Q2 results with revenue growth, positive market response, and improved customer diversification. The company exceeded analyst revenue and Adjusted EBITDA estimates but missed on EPS. Analyst questions focused on the growth prospects of automotive customer wins, sustainability of wallet …

HireQuest (HQI) awards director Jack A. Olmstead 4,811 restricted shares for board service

HireQuest, Inc. (HQI) has awarded Director Jack A. Olmstead a total of 4,811 restricted shares as compensation for his board service. These shares were granted on August 12, 2026, with 811 shares awarded in lieu of a quarterly cash retainer and 4,000 shares as …

HireQuest (HQI) grants director Kathleen Shanahan 4,000 restricted shares

HireQuest, Inc. director Kathleen M. Shanahan received a grant of 4,000 restricted common shares as an Annual Award under the company's 2019 Non-Employee Director Compensation Plan. These shares, valued at $16.64 each on the grant date of August 12, 2026, will vest on June …

Why Questerre Energy Corporation stock is rising today

Quest Diagnostics (DGX) Is Up 2.29% in One Week: What You Should Know

Momentum investing revolves around the idea of following a stock's recent trend in either direction. In "long context," investors will be essentially be "buying high, but hoping to sell even higher." With this methodology, taking advantage of trends in a stock's price is key; …

T. Rowe Price Associates (DGX) discloses 5.43M Quest Diagnostics shares in 13G/A

T. Rowe Price Associates, Inc. filed an amended Schedule 13G, reporting a beneficial ownership of 5,428,244 shares, or 4.9% of Quest Diagnostics Inc. common stock. The firm holds sole voting power over 5,321,387 shares and sole dispositive power over all 5,428,244 shares, while explicitly …

Assenagon Asset Management S.A. Acquires 4,334 Shares of Quest Diagnostics Incorporated $DGX

Assenagon Asset Management S.A. increased its stake in Quest Diagnostics Incorporated by 39.1% in the second quarter, acquiring 4,334 shares and bringing its total holdings to 15,405 shares valued at approximately $3.27 million. The medical research company reported strong Q2 earnings, exceeding estimates with …

Quest Resource (QRHC) Q2 2026 Earnings Call Transcript

Image source: The Motley Fool. DATE Thursday, Aug. 6, 2026 at 5:00 p.m. ET CALL PARTICIPANTS Alpha IR Group - Nick NelsonChief Executive Officer - Perry MossChief Financial Officer - Brett Johnston TAKEAWAYS Revenue -- $64.1 million, an increase of 7.6% compared to the …

Quest Diagnostics Inc (DGX) Technical Analysis: Support, Resistance, Indicators & Moving Averages

This article provides a technical analysis of Quest Diagnostics Inc (DGX), detailing its current price momentum score, support and resistance levels, and indicator readings. It shows that DGX has a momentum score of 3.90, trading between resistance at $249.41 and support at $213.38. The …

HireQuest Maintains Quarterly Dividend at $0.06 a Share, Payable on Sept. 15 to Shareholders of Record on Sept. 1

HireQuest, Inc. announced it is maintaining its quarterly dividend of $0.06 per share. The dividend is payable on September 15, 2026, to shareholders of record as of September 1, 2026. This news was published on August 13, 2026, at 05:59 pm EDT.

HireQuest declares $0.06 dividend

* HireQuest (HQI [https://seekingalpha.com/symbol/HQI]) declares $0.06/share quarterly dividend [https://seekingalpha.com/pr/20619094-hirequest-inc-declares-quarterly-dividend], in line with previous. * Forward yield [https://seekingalpha.com/symbol/HQI/dividends/yield?source=news_bullet] 1.38% * Payable Sept. 15; for shareholders of record Sept. 1; ex-div Sept. 1. * See HQI Dividend Scorecard, Yield Chart, & Dividend Growth. [https://seekingalpha.com/symbol/HQI/dividends?source=news_bullet] MORE ON …

HireQuest declares $0.06 quarterly dividend

HireQuest, Inc. (NASDAQ:HQI) has announced a quarterly dividend of $0.06 per share, payable on September 15, 2026, to shareholders of record as of September 1, 2026. HireQuest is a franchisor specializing in staffing solutions across the U.S. and international markets, offering temporary, direct-hire, and …

LifeSci Capital Maintains Aquestive Therapeutics(AQST.US) With Buy Rating, Maintains Target Price $10

LifeSci Capital analyst Francois Brisebois has reaffirmed a Buy rating for Aquestive Therapeutics (AQST.US), maintaining a target price of $10. According to TipRanks data, Brisebois has a 43.0% success rate and a 6.3% average return over the past year. This report highlights the analyst's …

Quest Diagnostics Incorporated (NYSE:DGX) Plans Quarterly Dividend of $0.86

Quest Diagnostics (NYSE:DGX) has declared a quarterly dividend of $0.86 per share, payable on October 21st to shareholders of record on October 6th. This dividend represents an annualized payout of $3.44 and a 1.4% yield. The company has a strong dividend history, having increased …

Aquestive Therapeutics, Inc. (NASDAQ:AQST) Receives Average Recommendation of "Buy" from Analysts

Aquestive Therapeutics (NASDAQ:AQST) has received an average "Buy" rating from analysts, with a consensus 12-month price target of $8.50. Despite exceeding second-quarter revenue expectations, the company reported a larger-than-expected loss per share and issued full-year revenue guidance below analyst consensus. Insider selling and institutional …

Aquestive Therapeutics (AQST) Stock Faces Cash Burn Questions As Anaphylm Nears Resubmission

Aquestive Therapeutics (AQST) stock experienced a 4% dip despite positive Q2 results showing increased liquidity and reaffirmed revenue guidance. The company is nearing resubmission of its Anaphylm New Drug Application, with management addressing FDA concerns. However, ongoing adjusted EBITDA losses and the dependence on …

Quest Diagnostics Keeps Quarterly Dividend at $0.86 per Share, Payable Oct. 21, to Shareholders of Record Oct. 6

Quest Diagnostics (DGX) announced that it will maintain its quarterly dividend at $0.86 per share. This dividend will be payable on October 21, 2026, to shareholders of record as of October 6, 2026. The announcement was published on August 12, 2026, by MT Newswires.

Questerre Energy Q2 Earnings Call Highlights

Key Points Interested in Questerre Energy Co.? Here are five stocks we like better. PX Energy delivered record quarterly profit and positive cash flow, contributing significantly to Questerre's results with average production of 5,700 barrels per day. The company is targeting more than CAD …

Quest Diagnostics Declares Quarterly Cash Dividend

SECAUCUS, N.J., Aug. 12, 2026 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), a leader in diagnostic information services, today announced that its Board of Directors declared a quarterly cash dividend of $0.86 per share, payable on October 21, 2026 to shareholders of record of Quest …

Quest Diagnostics Sets Oct. 21 Date for Cash Dividend

Quest Diagnostics (NYSE: DGX) has announced a quarterly cash dividend of $0.86 per share. The dividend will be payable on October 21, 2026, to shareholders of record as of October 6, 2026. This move reflects the company's commitment to providing direct cash returns to …

Aquestive Therapeutics Releases Q2 2026 Financial Results

Aquestive Therapeutics (AQST) reported a Q2 2026 diluted loss per share of $0.18, exceeding the expected loss of $0.11, with total revenue reaching $13.8 million, a 38.0% increase year-over-year. The company's net loss for the quarter was $22.9 million, and it ended with $98.5 …

Aquestive Therapeutics, Inc. 2026 Q2 - Results - Earnings Call Presentation (NASDAQ:AQST) 2026-08-12

Aquestive Therapeutics, Inc. (AQST) published its Q2 2026 earnings call presentation on August 12, 2026. The company reported an EPS of -$0.07, beating estimates by $0.05, and revenue of $13.82 million, a 38.15% year-over-year increase, beating estimates by $2.26 million. This presentation provides details …

Earnings call transcript: Questerre Energy posts Q2 2026 profit as PX Energy turns a corner

Key Points Interested in Questerre Energy Co.? Here are five stocks we like better. PX Energy delivered record quarterly profit and positive cash flow, contributing significantly to Questerre's results with average production of 5,700 barrels per day. The company is targeting more than CAD …

Aquestive Therapeutics (NASDAQ:AQST) Shares Gap Down Following Weak Earnings

Aquestive Therapeutics Q2 Earnings Call Highlights

Key Points Interested in Aquestive Therapeutics, Inc.? Here are five stocks we like better. Aquestive plans to resubmit Anaphylm's FDA application before the end of Q3 after revised packaging and instructions substantially reduced pouch-opening, film-tearing and administration errors in validation studies. Management is assuming …

Earnings call transcript: Aquestive Therapeutics tops revenue views in Q2 2026

Aquestive Therapeutics reported Q2 2026 revenue of $13.82 million, exceeding analyst estimates, but also posted a wider-than-expected loss of $0.18 per share due to an $11.7 million debt extinguishment charge. The company remains on track to resubmit its Anaphylm NDA to the FDA in …

Queste Communications Reports July Cash Outflow on Major Investment Activity

Questerre Energy Corporation Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026

HireQuest (HQI) Stock Jumps As Profit Margins Reset Higher

Aquestive Therapeutics Q2 Loss Widens, Revenue Rises

Aquestive Therapeutics reported a wider net loss in Q2 compared to the previous year, despite an increase in total revenue. The company also updated its full-year 2026 outlook, anticipating total revenue to be between $58 million and $62 million, with non-GAAP adjusted EBITDA expected …

Aquestive Therapeutics (AQST) Reports Q2 Loss, Tops Revenue Estimates

Aquestive Therapeutics (NASDAQ:AQST) Releases Earnings Results, Misses Expectations By $0.08 EPS